Emerging studies suggest this peptide, a dual stimulator targeting both GLP-1 and another hormone, may offer a promising development for obesity treatment. Early clinical investigations have demonstrated substantial reductions in visceral mass , conceivably exceeding other obesity treatments. However , additional study is necessary to fully assess